NEW YORK (GenomeWeb) – BG Medicine today reported a 41 percent decline year over year in its first quarter revenues. 

For the three months ended March 31, the Waltham, Massachusetts-based firm said that revenues totaled $437,000, down from $739,000 in Q1 2014. BG Medicine said that the drop resulted from a decline in orders from its largest clinical laboratory customer. 

Net loss for the recently completed quarter narrowed to $1.3 million, or $.04 per share, compared to a net loss of $2.2 million, or $.08 per share, in Q1 2014.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.